AI-based solution for brain age evaluation and Alzheimer's disease prediction

基于人工智能的大脑年龄评估和阿尔茨海默病预测解决方案

• 批准号: 10072254
• 金额: $ 45.72万
• 依托单位: INFERVISION UK LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10072254
• 关键词: AI; based; solution; brain; age

Dementia is the leading cause of death in the UK. Around 850,000 individuals are living with dementia, but only around 540,000 of these have received a diagnosis. An accurate early, or timely diagnosis of dementia can have many benefits including opening the door to future care and treatment. Dementia is a profoundly life-changing condition and reactions to a diagnosis can range from dismay and deep sadness to anger and despair. Early diagnosis allows people with dementia to receive appropriate treatment that can potentially help them maintain their cognitive function and quality of life for longer.The proprietory AI solution developed by Infervision offers accurate and early stage dementia diagnosis and characterisation, and predicts the pre-symptomatic risk of developing dementia with high accuracy using MRI scans. Infervision's solution represents a breakthrough that would provide an automated, extensible, and personalised healthcare platform for assisting the clinical diagnosis of tissue modifying diseases using multi-modal imaging and non-imaging MRI data; useful for both the treatment of patients, and importantly, in the development of novel therapeutics. The cutting-edge technology can analyse scans automatically and intelligently to deliver sensitive and precise micro-structural information about important tissue and organ structures, which can then be compared to data from healthy populations to identify the signs of dementia.It is believed that this Infervision's AI solution has the potential to accelerate clinical pathways, standardise quality of care, improve patient outcomes, and save time during assessments for Dementia, as well as contribute to the development of disease-modifying therapies. The solution is intended to become a routine part of clinical practice and drug development because it provides clinicians, researchers, and imaging centres with reliable, quantitative, and objective diagnostic and prognostic data using the results of our intelligent analysis.

在英国，痴呆症是主要的死亡原因。大约有85万人患有痴呆症，但其中只有大约54万人得到了诊断。准确、早期或及时地诊断痴呆症可以有许多好处，包括为未来的护理和治疗打开大门。痴呆症是一种深刻改变生活的疾病，对诊断的反应可能从沮丧和深深的悲伤到愤怒和绝望。早期诊断使痴呆症患者能够接受适当的治疗，有可能帮助他们更长时间保持认知功能和生活质量。由Infervision开发的专有AI解决方案提供准确的早期痴呆症诊断和特征，并使用MRI扫描高精度预测出现症状前的痴呆症风险。Infervision的解决方案代表着一项突破，它将提供一个自动化、可扩展和个性化的医疗平台，利用多模式成像和非成像MRI数据辅助组织改进性疾病的临床诊断；这对患者的治疗以及重要的新疗法的开发都很有用。这项尖端技术可以自动和智能地分析扫描，提供关于重要组织和器官结构的敏感和精确的微观结构信息，然后将这些信息与来自健康人群的数据进行比较，以识别痴呆的迹象。据信，这种Infervision的人工智能解决方案具有加快临床路径、标准化护理质量、改善患者结局、节省痴呆症评估期间的时间，以及为疾病修改疗法的开发做出贡献的潜力。该解决方案旨在成为临床实践和药物开发的常规部分，因为它使用我们的智能分析结果为临床医生、研究人员和成像中心提供可靠、定量和客观的诊断和预后数据。